The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. - Wikidata - wikimedia - TriplyDB

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

http://www.wikidata.org/entity/Q36403243

about

The dual role of complement in cancer and its implication in anti-tumor therapy Complement regulation of T-cell alloimmunity Complement regulation of T cell immunity Complement in monoclonal antibody therapy of cancer A novel role for CD55 in granulocyte homeostasis and anti-bacterial host defense Complement System Part II: Role in Immunity C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells.A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.Role and mechanism of action of complement in regulating T cell immunity.Complement system in lung disease.Complement modulation of T cell immune responses during homeostasis and disease.Immune cell-derived C3a and C5a costimulate human T cell alloimmunity.A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma.Toxicology of autoimmune diseases.Modulation of the antitumor immune response by complement.Decay-accelerating factor regulates T-cell immunity in the context of inflammation by influencing costimulatory molecule expression on antigen-presenting cells.Complement regulation of T-cell alloimmunity.Decay-accelerating factor 1 deficiency exacerbates leptospiral-induced murine chronic nephritis and renal fibrosis.Effect of complement and its regulation on myasthenia gravis pathogenesis.The role of complement in tumor growth Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1.Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo.C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity.Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55 Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis.T-cell regulation: with complements from innate immunity.Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.Properdin: New roles in pattern recognition and target clearance.Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection Significance of glycosylphosphatidylinositol-anchored protein enrichment in lipid rafts for the control of autoimmunity.Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.

P2860

Q26738682-3AF79BEE-38A8-4B9C-A51A-4D4B57F7AAF1 Q26823956-EE34AB0A-2F17-419C-9296-921C81372655 Q26827470-F6F9F677-EBA7-4CF1-A593-8CA0856FB7FE Q26860800-1A07BD1B-90D2-4B15-ABCC-E275B003CB1C Q28250093-9AEC9032-7F6F-40ED-B790-041C34CFF48C Q28263460-B9413D5E-D705-4992-896F-44D49F6D56B3 Q30274884-4D5D8274-B867-4713-8EE4-2F5C786F2A5F Q33240464-0E6C84F9-28C9-493F-A5C2-B3B801E7DE3D Q33410671-7153A2FD-8034-4EAE-BB58-BAA9B6289F52 Q33570304-2D1B689F-8959-4D55-AE0D-A6F029504D17 Q33711147-01DCF271-5F6D-4322-ABEF-21C734576960 Q34072846-66207610-0F75-4D89-9E48-65DE70E94452 Q34305533-57DED7DC-F15E-479F-B369-FDF472526A0E Q34341409-51D5A22C-9D88-40CF-B70E-6A6E16ACCD73 Q34370940-DF3DF090-70D1-4BB7-87BB-3738C304A0F4 Q34416391-7D340098-A9BB-46AC-96C6-6A54419C5F80 Q34788943-90AD34DB-3157-46AE-93BF-F635EF4FA5A5 Q34838919-B46BC6F4-733D-4ACB-8908-A99F60446B5F Q35140939-5C041E43-FC88-4F86-BE3E-22BBE6CABA53 Q35151737-0C269E2F-B7C2-460B-A5C3-0DAE65DD4458 Q35208137-5B13AD79-4827-442F-AEA4-7D04106A3645 Q35221722-F8DB2D87-86D9-4CC8-8BAB-206AAD257C97 Q35231345-03FB6F43-5CDD-4CA1-82C6-21EDA64E734C Q35536219-63F7CF6B-8610-4DA9-9367-87898FD63155 Q35578822-E5E0E0E3-0609-4ED4-8CC4-6CC18F4D6F42 Q35691607-0651E998-1861-4C21-A8D2-DB9F1EC975DE Q35850677-1CCDBC0B-8D0F-4091-B922-C1B8DCE15333 Q35884221-B5DF278F-D946-4F2F-8560-D907B4EACB61 Q35914730-8721775E-8B29-47CF-8859-2D16E965C7CB Q36105385-DFBFCDEA-7F94-42F4-8595-0B978D670225 Q36426921-D0DFB7E7-AA6F-4071-AFB8-A90342144A5E Q36471905-18942AB8-ACA8-466E-AA69-FE7F90516E43 Q36684909-1B631C28-C3B0-42C6-91C4-897CB16275E7 Q36718295-C27E9B80-C01E-4A5F-A029-7BA979C0AF70 Q36843709-7D03B45A-D2A6-4E25-BA0C-AEFA3114F821 Q37066042-416C307B-0973-40FF-A8C0-E87E4E7C7AAF Q37106187-43E1434D-18B6-492F-BFAB-A14DD2036B98 Q37106399-156D811C-F89D-42A3-B399-6C48262E1DAC Q37132162-3BD01535-7503-43D1-BBA7-DA2F99B9E094 Q37189823-976CAFA4-2674-4B60-A662-622FC9265283

P2860

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

http://www.wikidata.org/entity/Q36403243

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

@ast

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

@en

type

label

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

@ast

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

@en

prefLabel

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

@ast

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

@en

P1433

Q36403243-4AEED1C4-6901-46DD-B781-C58BE984AE52

P1476

Q36403243-3593B42B-3C72-483E-A88B-7C0E4B141BC0

P2093

Q36403243-22F64AD4-25EB-4480-8F45-5210B9E988A5

Q36403243-30C558AD-76A0-4C6A-ADCD-BB129BBA7259

Q36403243-51F4A8E9-8BD5-43C9-93EC-9C28C8E88258

Q36403243-90978F38-3CA4-47BF-9E37-5BA4FBBD2350

Q36403243-EAD94E70-AA95-47DB-9233-38C8B4618F57

Q36403243-F63EA780-D11F-4855-B24B-1FA2DD62E9A3

P2860

Q36403243-0BEF603D-D6BE-413F-8552-DB527E364AB9

Q36403243-0FA29F12-B7DE-4DA1-A596-C811A971AF96

Q36403243-118ADCFE-E6A4-4CB1-8A2D-B4352107A8CE

Q36403243-1A4311AD-66F6-4C94-BBFB-742F088085DE

Q36403243-2409012A-5C0F-4E59-A631-476D0EFE3AF1

Q36403243-2882F089-0AD1-4FB3-A300-CC1AA3A9E7A1

Q36403243-2A5844E7-5EF5-4B55-B699-EB0AA0EBB87E

Q36403243-2A773DDA-7F1F-4103-9B35-412C388C9C76

Q36403243-2AF01026-6967-4335-90A6-1AD5CE18441E

Q36403243-2B9BC527-CC00-4322-89B2-136830EC32F7

P304

Q36403243-9172516E-5479-4F34-86EC-5B7E3382D7A3

P31

Q36403243-8348146B-3357-46AB-88F1-8228302C7000

P356

Q36403243-B890DCE9-5C3D-4D3B-AD5D-9AA785C08F10

P407

Q36403243-52830189-F415-45D3-BF86-D79ABFBC608D

P433

Q36403243-900A2C75-C0FC-41E8-918A-F23D6DF6B2D8

P478

Q36403243-01E92EC6-CD2F-4496-B919-3B9A44114B10

P50

Q36403243-EBFB356D-DDA3-43B2-9C74-FCB519E79F32

P577

Q36403243-0E062EB3-363F-4318-B470-A32B90128C4F

P5875

Q36403243-94A353D2-55A0-472E-8E97-680D3FB13FE4

P698

Q36403243-B55A7E42-C6D5-4345-9A76-75EB7B0FA73C

P932

Q36403243-65653DD8-1BB4-4738-AC39-F03920B1E6AD

P356

P1433

Journal of Experimental Medicine

P1476

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

@en

P2093

Andrew D Wells

http://www.w3.org/2001/XMLSchema#string

Brendan Hilliard

http://www.w3.org/2001/XMLSchema#string

Jianuo Liu

http://www.w3.org/2001/XMLSchema#string

Takashi Miwa

http://www.w3.org/2001/XMLSchema#string

Wen-Chao Song

http://www.w3.org/2001/XMLSchema#string

Youhai Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype

Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain

The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)

CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation

Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55)

Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

Complement. First of two parts

Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

P304

567-577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20040863

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P50

John D. Lambris

P577

2005-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8021860

http://www.w3.org/2001/XMLSchema#string

P698

15710649

http://www.w3.org/2001/XMLSchema#string

P932

2213052

http://www.w3.org/2001/XMLSchema#string